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Dementia and statins
Sir—The case-control observational
study by Hershel Jick and colleagues
(Nov 11, 1627)1 raises some important
questions over and above researchers’
own caveats.
First, the diagnosis of dementia was
based on a clinical assessment by family
physicians, which is only a first step
towards a diagnosis. Quantitative
screening is needed to ascertain loss of
cognition, such as the mini-mental
state examination.2 A score of less than
24 should lead to a more specific
diagnostic assessment.3 Moreover,
causes of cognitive failure other than
dementia proper, should be excluded,
such as pharmacologically or
toxicologically induced disturbances of
brain function.
Second, Jick and colleagues mention
the possibility that the reduced risk for
statins could be caused by
characteristics of the statin recipients
that are associated with a lower risk of
dementia. They should have expanded
this point, since they were close to
touching on the fundamental weakness
of the study: bias by indication.
Sociological experience shows a group
of intelligent, well informed, alert,
mostly urban patients. If they develop
hypercholesterolaemia, they frequently
demand and obtain the most modern
lipid-lowering agents. By contrast,
other patients, generally of lower
socioeconomic status, are less aware of
cardiovascular risk factors and
treatment trends. In the Systolic
Hypertension in Europe trial,4 age on
leaving school was a major determinant
of cognitive function, measured by the
mini-mental state questionnaire.
This type of preordained selection
might partly explain the negative
association between dementia and the
use of statins, rather than a
pharmacological action of this drug
class.
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Sir—Hershel Jick and colleagues1
found a striking inverse association
between the use of statins and
dementia.1 They admit that case-
control studies merely identify
associations, not causal links, which
could be the case in their study. 
Since 87% of participants were older
than 70 years, the use of statins in this
population was probably affected by
many factors, including state of health,
quality of life, and prognosis. Healthy
people in their 70s will not be denied
statins. Indeed treatment in such
individuals at high risk of cardiovascular
events has a low number needed to
treat, which suggests cost effectiveness.2
Nearly all guidelines advise caution in
prescribing statins to people with non-
cardiovascular diseases that impair
prognosis for a healthy life.3 A person
who has dementia is much less likely
than someone without to be prescribed
statins. In Jick and colleagues’ study,
only 12 (4·2%) of 284 cases were
receiving statins, compared with 100
(9·3%) of 1080 controls. The
proportion of people receiving statins is
strikingly low among cases and fairly
low even in the controls.
Many randomised prospective trials
of statins shed light on the effect of
these drugs on the development of
dementia. Jick and colleagues should
nevertheless be congratulated on
highlighting an important imbalance in
the prescription of statins. If it is
confirmed, what should be debated is
whether statins should or should not be
withheld from people with dementia. 
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Authors’ reply
Sir—In reply to W H Birkenhäger and
colleagues, we point out that in another
study of the effects of oestrogen-
replacement therapy on the
development of Alzheimer’s disease we
carefully assessed 80 case records of
patients recorded as having dementia
or Alzheimer’s disease, through the
General Practice Research Database.
90% met stringent criteria for the
diagnosis.1
We controlled for patients’ general
practice in our analysis. Although
general practice provides only an
indirect indicator of socioeconomic
status and education, we suspect that it
substantially controls for these factors,
as well as for the acumen of and criteria
for diagnosing dementia of the
individual physicians. We suggest that
specific choice of drugs, as well as the
decision to treat hyperlipidaemia is not
involved in any selection bias, since
treatment with non-statin lipid-
lowering agents had no effect on the
risk of dementia. 
Birkenhäger and colleagues allude to
the pharmacological action of statins.
However, statins have beneficial effects
on vascular endothelium through the
increase in activity of endothelial nitric-
oxide synthase and the reduction of
endothelin-1,2,3 and their effects in
reducing heart disease and stroke4,5
exceed their lipid-lowering actions.
B M Y Cheung and C R Kumana
seem to assume that we studied
prevalent cases of dementia. We
included only incident cases of
dementia. Therefore the data on statin
use relate only to the time before the
diagnosis. The indication for use was
hyperlipidaemia in all statins users.
The negative association between
statins and dementia was present for all
durations of treatment, including 4 or
more years before the date of first
diagnosis. Our results provide
information on the use of statins before
